The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1447
ISSUE1447
July 21, 2014
Ceritinib (Zykadia) for Non-Small Cell Lung Cancer
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ceritinib (Zykadia) for Non-Small Cell Lung Cancer
July 21, 2014 (Issue: 1447)
Ceritinib (Zykadia – Novartis), an oral tyrosine
kinase inhibitor, has received accelerated approval
from the FDA for treatment of patients with anaplastic
lymphoma kinase (ALK)-positive metastatic
non-small cell lung cancer (NSCLC) who...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.